Journal of Hepatology
Volume 51, Issue 4 , Pages 655-666 , October 2009

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C

  • Pierre-Yves Bochud

      Affiliations

    • Department of Internal Medicine, Infectious Diseases Service, CHUV, Lausanne, Switzerland
    • Institute of Microbiology, University of Lausanne, CHUV, Lausanne, Switzerland
    • ,
  • Tao Cai

      Affiliations

    • Department of Internal Medicine, Infectious Diseases Service, CHUV, Lausanne, Switzerland
    • Institute of Microbiology, University of Lausanne, CHUV, Lausanne, Switzerland
    • ,
  • Kathrin Overbeck

      Affiliations

    • Division of Clinical Pathology, University Hospitals, Geneva, Switzerland
    • ,
  • Murielle Bochud

      Affiliations

    • Institute for Social and Preventive Medicine, CHUV, Lausanne, Switzerland
    • ,
  • Jean-François Dufour

      Affiliations

    • Division of Clinical Pharmacology, University Hospital, Bern, Switzerland
    • ,
  • Beat Müllhaupt

      Affiliations

    • Division of Gastroenterology and Hepatology, University Hospital of Zurich, Switzerland
    • ,
  • Jan Borovicka

      Affiliations

    • Division of Gastroenterology, Canton Hospital, St. Gallen, Switzerland
    • ,
  • Markus Heim

      Affiliations

    • Division of Gastroenterology and Hepatology, University Hospital of Basel, Switzerland
    • ,
  • Darius Moradpour

      Affiliations

    • Division of Gastroenterology and Hepatology, CHUV, Lausanne, Switzerland
    • ,
  • Andreas Cerny

      Affiliations

    • Clinica Moncucco, Lugano, Switzerland
    • ,
  • Raffaele Malinverni

      Affiliations

    • Pourtalès Hospital, Neuchâtel, Switzerland
    • ,
  • Patrick Francioli

      Affiliations

    • Division of Hospital Preventive Medicine, CHUV, Lausanne, Switzerland
    • ,
  • Francesco Negro

      Affiliations

    • Division of Clinical Pathology, University Hospitals, Geneva, Switzerland
    • Division of Gastroenterology and Hepatology, University Hospitals of Geneva, 24 rue Micheli-du-Crest, 1211 Geneva, Switzerland
    • Corresponding Author InformationCorresponding author. Tel.: +41 22 3729355; fax: +41 22 3729366.
    • ,
  • on behalf of the Swiss Hepatitis C Cohort Study Group

      Affiliations

    • The members of the Swiss Hepatitis C Cohort Study Group are listed in the Appendix.

Received 8 February 2009 ,Revised 9 April 2009 ,Accepted 5 May 2009.

References 

  1. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol. 2006;44:S6–S9
  2. Lauer GM, Walker BD. Hepatitis C virus infection. N Eng J Med. 2001;345:41–52
  3. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol. 2006;44:S19–S24
  4. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F. Steatosis in chronic hepatitis C: why does it really matter?. Gut. 2006;55:123–130
  5. Castera L, Hezode C, Roudot-Thoraval F, Bastie A, Zafrani ES, Pawlotsky JM, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52:288–292
  6. Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol. 2003;38:257–265
  7. Poynard T, Ratziu V, Charlotte F, Goodman Z, McHutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol. 2001;34:730–739
  8. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825–832
  9. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30:1054–1058
  10. Datz C, Cramp M, Haas T, Dietze O, Nitschko H, Froesner G, et al. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre. Gut. 1999;44:563–567
  11. Deuffic-Burban S, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat. 2002;9:114–122
  12. Yi Q, Wang PP, Krahn M. Improving the accuracy of long-term prognostic estimates in hepatitis C virus infection. J Viral Hepat. 2004;11:166–174
  13. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology. 2008;48:418–431
  14. Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut. 2004;53:451–455
  15. Prasad L, Spicher VM, Zwahlen M, Rickenbach M, Helbling B, Negro F. Cohort profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol. 2007;36:731–737
  16. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology. 2006;130:1636–1642
  17. Dhumeaux D, Marcellin P, Lerebours E. Treatment of hepatitis C. The 2002 French consensus. Gut. 2003;52:1784–1787
  18. Ostapowicz G, Watson KJ, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis C virus infection. Hepatology. 1998;27:1730–1735
  19. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215–1219
  20. Asselah T, Boyer N, Guimont MC, Cazals-Hatem D, Tubach F, Nahon K, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut. 2003;52:1638–1643
  21. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, et al. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004;53:406–412
  22. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428–434
  23. Monto A, Alonzo J, Watson JJ, Grunfeld C, Wright TL. Steatosis in chronic hepatitis C: relative contributions of obesity, diabetes mellitus, and alcohol. Hepatology. 2002;36:729–736
  24. Harris HE, Eldridge KP, Harbour S, Alexander G, Teo CG, Ramsay ME. Does the clinical outcome of hepatitis C infection vary with the infecting hepatitis C virus type?. J Viral Hepat. 2007;14:213–220
  25. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358–1364
  26. Boccato S, Pistis R, Noventa F, Guido M, Benvegnù L, Alberti A. Fibrosis progression in initially mild chronic hepatitis C. J Viral Hepat. 2006;13:297–302
  27. Perumalswami P, Kleiner DE, Lutchman G, Heller T, Borg B, Park Y, et al. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection. Hepatology. 2006;43:780–787
  28. An P, Bleiber G, Duggal P, Nelson G, May M, Mangeat B, et al. APOBEC3G genetic variants and their influence on the progression to AIDS. J Virol. 2004;78:11070–11076

☆ The authors who have taken part in this study declared that they do not have anything to disclose regarding funding from industry or conflict of interest with respect to this manuscript.

PII: S0168-8278(09)00386-9

doi: 10.1016/j.jhep.2009.05.016

Journal of Hepatology
Volume 51, Issue 4 , Pages 655-666 , October 2009

Article Tools

* Image Usage & Resolution